TumCI Cancer Research Results

TumCI, Tumor Cell invasion: Click to Expand ⟱
Source:
Type:
Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.
Scientific Papers found: Click to Expand⟱
1911- Nos,    Noscapine inhibits tumor growth in TMZ-resistant gliomas
- in-vitro, GBM, NA - in-vivo, GBM, NA
TumCG↓, TumCI↓, OS↑,
1130- OA,    Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-κB Signaling Pathway in Human Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCI↓, TumCMig↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓,
4628- OLE,    Effects of oleuropein on tumor cell growth and bone remodelling: Potential clinical implications for the prevention and treatment of malignant bone diseases
- in-vitro, Var, NA
chemoPv↑, TumCP↓, angioG↓, TumCI↓, TumMeta↓,
1225- OLST,    Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway
- vitro+vivo, PC, NA
TumCMig↓, TumCI↓, Ferroptosis↑, MAPK↓,
1231- PBG,    Caffeic acid phenethyl ester inhibits MDA-MB-231 cell proliferation in inflammatory microenvironment by suppressing glycolysis and lipid metabolism
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCMig↓, TumCI↓, MMP↓, TLR4↓, TNF-α↓, NF-kB↓, IL1β↓, IL6↓, IRAK4↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ACC↓, FASN↓, eff↓,
2381- PBG,    Chinese Poplar Propolis Inhibits MDA-MB-231 Cell Proliferation in an Inflammatory Microenvironment by Targeting Enzymes of the Glycolytic Pathway
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCMig↓, TumCI↓, angioG↓, TNF-α↓, IL1β↓, IL6↓, NLRP3↓, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDHA↓, ROS↑, MMP↓,
4922- PEITC,    Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms
- Review, Var, NA
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
4926- PEITC,    PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT
- in-vitro, CRC, SW48
TumCI↓, TumCMig↓, EMT↓, Smad1↓, AntiCan↑, Snail↓, Slug↓, Zeb1↓, ZEB2↓, TGF-β1↓, eff↑, E-cadherin↑, N-cadherin↓, Vim↓,
4931- PEITC,    Phenethyl isothiocyanate (PEITC) suppresses prostate cancer cell invasion epigenetically through regulating microRNA-194
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
Risk↓, miR-194↑, TumCI↓, MMP2↓, MMP9↓, BMP2↓, *chemoPv↑,
4933- PEITC,    Phenethyl isothiocyanate inhibits metastasis potential of non-small cell lung cancer cells through FTO mediated TLE1 m6A modification
- vitro+vivo, Lung, H1299 - vitro+vivo, SCC, H226
AntiCan↓, TumCP↓, TumMeta↓, ChemoSen↑, tumCV↓, TumCI↓, TumCMig↓, FTO↓, TLE1↓, Akt↓, NF-kB↓,
1256- PI,    Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models
- in-vitro, adrenal, PHEO - in-vivo, NA, NA
Apoptosis↑, ROS↑, TumCMig↓, TumCI↓, EMT↓, angioG↓, Necroptosis↑, MAPK↑, ERK↑,
5211- PI,    Piperine inhibits colorectal cancer migration and invasion by regulating STAT3/Snail-mediated epithelial-mesenchymal transition
- in-vitro, CRC, NA
TumCMig↓, TumCI↓, EMT↓, Snail↓, STAT3↓,
1131- PI,    Piperlongumine‑loaded nanoparticles inhibit the growth, migration and invasion and epithelial‑to‑mesenchymal transition of triple‑negative breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549
TumCG↓, tumCV↓, TumCMig↓, TumCI↓, MMP2↓, Slug↓, N-cadherin↓, β-catenin/ZEB1↓, SMAD3↓, E-cadherin↑, EMT↓,
1939- PL,    Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP
- in-vitro, HCC, HepG2 - in-vitro, HCC, HUH7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, ER Stress↑, selectivity↑, tumCV↓, ROS↑, GSH↓, eff↓, Ca+2↑, MAPK↑, CHOP/DDIT3↑, Dose↝,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP/DDIT3↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp/ABCB1↓, MDR1↓, MRP1/ABCC1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2/PTGS2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP/DDIT3↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
2952- PL,    Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization
- in-vitro, Bladder, T24/HTB-9 - in-vivo, Bladder, NA
TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, ROS↑, Slug↓, β-catenin/ZEB1↓, Zeb1↓, N-cadherin↓, F-actin↓, GSH↓, EMT↓, CLDN1↓, ZO-1↓,
2961- PL,    Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis
- in-vitro, ESCC, KYSE-30
Pyro↑, TumCP↓, TumCMig↓, TumCI↓, ASC↑, cl‑Casp1↑, NLRP3↑, GSDMD↑, ROS↑, NRF2↓, TXNIP↑,
4965- PSO,  Cisplatin,    The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis
- vitro+vivo, GC, HGC27 - vitro+vivo, GC, MKN45
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, *toxicity↓, eff↑, Ferroptosis↑, ACSL4↑, GPx4↓, ChemoSen↑, chemoP↑, AntiTum↑, Sepsis↓,
1237- PTS,    Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade
- in-vitro, Ovarian, SKOV3
TumCMig↓, TumCI↓, MDA↑, ROS↑, BAX↑, Casp3↑, Bcl-2↓, SREBP1/SREBF1↓, FASN↓, AMPK↓, p‑AMPK↑, p‑P53↑, p‑TSC2↑, p‑Akt↓, p‑mTOR↓, p‑S6K↓, p‑4E-BP1↓,
1238- PTS,    Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention
- in-vitro, GC, NA - in-vivo, NA, NA
TumCCA↑, TumCP↓, TumCMig↓, TumCI↓, TumVol↓, TumW↓, Weight∅, JAK2↓, STAT3↓,
4699- PTS,    Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vivo, BC, MDA-MB-231
TumCMig↓, TumCI↓, E-cadherin↑, Snail↓, Slug↓, Vim↓, Zeb1↑, miR-205↑, Src↓, TumCG↓, FAK↓, EMT↓,
4689- PTS,    Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol
eff↑, TumCCA↑, ROS↑, MMP2↓, MMP9↓, CSCs↓, CD133↓, OCT4↓, SOX2↓, Nanog↓, STAT3↓, BioAv↑, TumCI↓, ROS↑, Apoptosis↑,
3929- PTS,    New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects
- Review, Var, NA - Review, Arthritis, NA
*NRF2↑, *BioAv↑, *ROS↓, *Inflam↓, *HO-1↑, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *hepatoP↑, *neuroP↑, *iNOS↓, *COX2/PTGS2↓, TumMeta↓, SOD2↓, ROS↑, TumCI↓, TumCG↓, HDAC1↓, PTEN↑, BP↓, *GutMicro↑,
2340- QC,    Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2)
- in-vitro, OS, NA
TumCG↓, GlucoseCon↓, TumCI↓, GLUT1↓, PKM2↓, LDHA↓, Glycolysis↓, lactateProd↓, HK2↓, eff↑,
3353- QC,    Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells
- in-vitro, Oral, KON - in-vitro, Nor, MRC-5
tumCV↓, selectivity↑, TumCCA↑, TumCMig↓, TumCI↓, Apoptosis↑, TumMeta↓, Bcl-2↓, BAX↑, TIMP1↑, MMP2↓, MMP9↓, *Inflam↓, *neuroP↑, *cardioP↑, p38↓, MAPK↓, Twist↓, P21↓, cycD1/CCND1↓, Casp3↑, Casp9↑, p‑Akt↓, p‑ERK↓, CD44↓, CD24↓, ChemoSen↑, MMP↓, Cyt‑c↑, AIF↑, ROS↑, Ca+2↑, Hif1a↓, VEGF↓,
3375- QC,    Quercetin Mediated TET1 Expression Through MicroRNA-17 Induced Cell Apoptosis in Melanoma Cells
- in-vitro, Melanoma, B16-BL6
TET1↑, TumCI↓,
3374- QC,    Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis
- Review, Oral, NA - Review, AD, NA
α-SMA↓, α-SMA↑, TumCP↓, tumCV↓, TumVol↓, TumCI↓, TumMeta↓, TumCMig↓, ROS↑, Apoptosis↑, BioAv↓, *neuroP↑, *antiOx↑, *Inflam↓, *Aβ↓, *cardioP↑, MMP↓, Cyt‑c↑, MMP2↓, MMP9↓, EMT↓, MMPs↓, Twist↓, Slug↓, Ca+2↑, AIF↑, Endon↑, P-gp/ABCB1↓, LDH↑, HK2↓, PKA↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, GRP78/BiP↑, Casp12↑, CHOP/DDIT3↑,
3373- QC,    The Effect of Quercetin in the Yishen Tongluo Jiedu Recipe on the Development of Prostate Cancer through the Akt1-related CXCL12/ CXCR4 Pathway
- in-vitro, Pca, DU145
TumCP↓, Casp3↑, Bcl-2↓, Apoptosis↑, TumCI↓, TumCMig↓, CXCL12↓, CXCR4↓,
56- QC,    Quercetin inhibits epithelial–mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial–mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells
- in-vitro, PC, PANC1 - in-vitro, PC, PATU-8988
EMT↓, MMPs↓, MMP2↓, MMP7↓, STAT3↓, TumCI↓, TumMeta↓, tumCV↓,
57- QC,    Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo
- vitro+vivo, PC, PC3
TSP-1↑, angioG↓, TumCMig↓, TumCI↓,
59- QC,    Quercetin Inhibits Breast Cancer Stem Cells via Downregulation of Aldehyde Dehydrogenase 1A1 (ALDH1A1), Chemokine Receptor Type 4 (CXCR4), Mucin 1 (MUC1), and Epithelial Cell Adhesion Molecule (EpCAM)
- in-vitro, BC, MDA-MB-231
ALDH1A1↓, CXCR4↓, MUC1↓, EpCAM↓, CSCs↓, TumCP↓, TumCI↓, CD44↓, CD24↓, Apoptosis↑, TumCCA↑,
60- QC,  EGCG,  isoFl,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, pCSCs
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, CSCs↓, Apoptosis↑, TumCMig↓, TumCI↓, CD44↓, CD133↓,
96- QC,  docx,    Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, PC3
PI3K/Akt↓, Ki-67↓, BAX↑, Bcl-2↓, EpCAM↓, Twist↓, E-cadherin↑, P-gp/ABCB1↓, TumCP↓, TumCMig↓, TumCI↓,
90- QC,  HYP,    Combination of quercetin and hyperoside inhibits prostate cancer cell growth and metastasis via regulation of microRNA‑21
- in-vitro, Pca, PC3
ROS↑, cl‑Casp3↑, cl‑PARP↑, miR-21↓, PDCD4↑, TAC↑, tumCV↓, TumCI↓,
85- QC,    Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3)
- in-vitro, Pca, PC3
uPA↓, uPAR↓, EGFR↓, NRAS↓, Jun↓, NF-kB↓, β-catenin/ZEB1↓, p38↑, MAPK↑, cJun↓, cFos↓, Raf↓, TumCI↓, TumCMig↓,
2332- RES,    Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism
- Review, Var, NA
Glycolysis↓, GLUT1↓, PFK1↓, Hif1a↓, ROS↑, PDH↑, AMPK↑, TumCG↓, TumCI↓, TumCP↓, p‑NF-kB↓, SIRT1↑, SIRT3↑, LDH↓, PI3K↓, mTOR↓, PKM2↓, R5P↝, G6PD↓, TKT↝, talin↓, HK2↓, GRP78/BiP↑, GlucoseCon↓, ER Stress↑, Warburg↓, PFK↓,
2441- RES,    Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions
- Review, Var, NA
*toxicity↓, *BioAv↝, *Dose↝, *hepatoP↑, *neuroP↑, *AntiAg↑, *COX2/PTGS2↓, *antiOx↑, *ROS↓, *ROS↑, PI3K↓, Akt↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, NRF2↑, GPx↑, HO-1↑, BioEnh?, PTEN↑, ChemoSen↑, eff↑, mt-ROS↑, Warburg↓, Glycolysis↓, GlucoseCon↓, GLUT1↓, lactateProd↓, HK2↓, EGFR↓, cMyc↓, ROS↝, MMPs↓, MMP7↓, survivin↓, TumCP↓, TumCMig↓, TumCI↓,
3083- RES,    Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
YAP/TEAD↓, Rho↓, FAK↓, MMP9↓, ChemoSen↑, RAS↓, ROCK1↓, TumCI↓, TumMeta↓,
3082- RES,    Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
VEGF↓, CXCL12↓, IL6↓, α-SMA↓, Hif1a↓, TumCI↓, EMT↓,
3086- RES,    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, DU145
TET1↑, TumCMig↓, TumCI↓, TIMP2↑, TIMP3↑, MMP2↓, MMP9↓,
3089- RES,    The Role of Resveratrol in Cancer Therapy
- Review, Var, NA
angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,
3095- RES,    Resveratrol suppresses migration, invasion and stemness of human breast cancer cells by interfering with tumor-stromal cross-talk
- in-vitro, BC, NA
TumCP↓, TumCMig↓, TumCI↓, cycD1/CCND1↓, cMyc↓, MMP2↓, MMP9↓, SOX2↓, Akt↓, STAT3↓, α-SMA↓,
3070- RES,    Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma
- in-vitro, RCC, ACHN - in-vitro, RCC, 786-O - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, NLRP3↓,
2988- RES,    The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation
- in-vitro, HCC, HUH7
TumCMig↓, TumCI↓, uPA↓, Sp1/3/4↓,
101- RES,    Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis
- in-vitro, GC, SGC-7901
HH↓, Gli1↓, EMT↓, Snail↓, N-cadherin↓, E-cadherin↑, TumCI↓, TumMeta↓,
877- RES,    Resveratrol Inhibits Invasion and Metastasis of Colorectal Cancer Cells via MALAT1 Mediated Wnt/β-Catenin Signal Pathway
- in-vitro, CRC, LoVo - in-vitro, CRC, HCT116
MALAT1↓, Wnt/(β-catenin)↓, TumCI↓, TumMeta↓,
7150- RES,    Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity
- Review, Var, NA
AntiTum↑, PI3K↓, Akt↓, *AntiAge↑, *SIRT1↑, *lipid-P↓, *ROS↓, *BioAv↓, *NRF2↑, *HO-1↑, SOD↑, HDAC1↓, PTEN↑, P53↑, TumCCA↑, TumCI↓, TumMeta↓, EMT↓, MMPs↓, MMP9↓, angioG↓, VEGF↓, EGFR↓, FGF21↓, HIF-1↓, *neuroP↑, *cardioP↑, BMPs↑, ROS↑, Vim↓, N-cadherin↓, MMP3↓, MMP13↓, E-cadherin↑, Ki-67↓,

Showing Research Papers: 351 to 400 of 467
Prev Page 8 of 10 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 467

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

CYP1A1↑, 1,   CYP2E1↑, 1,   Ferroptosis↑, 2,   GPx↑, 1,   GPx4↓, 1,   GSH↓, 7,   HO-1↑, 4,   MDA↑, 2,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 3,   Prx4↑, 1,   ROS↑, 18,   ROS↝, 1,   mt-ROS↑, 1,   SIRT3↑, 1,   SOD↑, 2,   SOD1↑, 1,   SOD2↓, 1,   SOD2↑, 1,   TAC↑, 1,   TKT↝, 1,   Trx↓, 1,   TrxR↓, 2,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 2,   ATP↓, 2,   MMP↓, 6,   OCR↓, 1,   Raf↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↓, 1,   ACSL4↑, 1,   AMPK↓, 1,   AMPK↑, 1,   p‑AMPK↑, 1,   cMyc↓, 5,   CYP3A4↓, 1,   FASN↓, 2,   FGF21↓, 1,   G6PD↓, 1,   GlucoseCon↓, 4,   GlutMet↓, 1,   Glycolysis↓, 8,   HK2↓, 8,   lactateProd↓, 3,   LDH↓, 1,   LDH↑, 1,   LDHA↓, 3,   PDH↑, 1,   PFK↓, 4,   PFK1↓, 1,   PI3K/Akt↓, 1,   PKM2↓, 4,   POLD1↓, 1,   R5P↝, 1,   p‑S6K↓, 1,   SIRT1↑, 2,   SREBP1/SREBF1↓, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 8,   p‑Akt↓, 3,   Apoptosis↑, 10,   BAX↑, 4,   Bcl-2↓, 8,   BIM↑, 1,   BMP2↓, 1,   cl‑Casp1↑, 1,   Casp12↑, 1,   Casp3↑, 7,   cl‑Casp3↑, 1,   Casp7↑, 3,   Casp8↑, 1,   Casp9↑, 2,   CK2↓, 1,   Cyt‑c↑, 4,   DR4↑, 1,   Endon↑, 1,   Fas↑, 1,   Ferroptosis↑, 2,   GSDMD↑, 1,   JNK↑, 1,   MAPK↓, 3,   MAPK↑, 3,   Mcl-1↓, 1,   MDM2↓, 1,   Necroptosis↑, 1,   p38↓, 1,   p38↑, 2,   PDCD4↑, 1,   Pyro↑, 1,   survivin↓, 5,   Telomerase↓, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 4,   p‑TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   miR-205↑, 1,   miR-21↓, 1,   other↝, 1,   TLE1↓, 1,   tumCV↓, 9,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 4,   p‑eIF2α↑, 1,   ER Stress↑, 3,   GRP78/BiP↑, 2,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↓, 1,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   P53↑, 3,   p‑P53↑, 1,   cl‑PARP↑, 2,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   P21↓, 1,   P21↑, 2,   RB1↓, 1,   p‑RB1↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,   ALDH1A1↓, 1,   CD133↓, 2,   CD24↓, 2,   CD44↓, 3,   cFos↓, 2,   cMET↓, 1,   CSCs↓, 4,   EMT↓, 16,   EpCAM↓, 2,   ERK↓, 2,   ERK↑, 1,   p‑ERK↓, 1,   FGF↑, 1,   FOXM1↓, 1,   p‑FOXO3↓, 1,   FOXO4↓, 1,   Gli1↓, 1,   GSK‐3β↓, 1,   HDAC1↓, 2,   HH↓, 1,   IGF-1↓, 1,   Jun↓, 1,   miR-194↑, 1,   mTOR↓, 4,   p‑mTOR↓, 1,   Nanog↓, 2,   NRAS↓, 1,   OCT4↓, 2,   PI3K↓, 5,   PTEN↑, 4,   RAS↓, 2,   SOX2↓, 3,   Src↓, 1,   STAT1↓, 1,   STAT3↓, 8,   STAT6↓, 1,   TOP2↓, 1,   TumCG↓, 8,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   AP-1↓, 1,   Ca+2↑, 3,   CLDN1↓, 1,   CXCL12↓, 2,   E-cadherin↑, 9,   F-actin↓, 1,   FAK↓, 2,   Fibronectin↓, 1,   FTO↓, 1,   ITGB1↓, 1,   ITGB6↓, 1,   Ki-67↓, 4,   LEF1↓, 1,   MALAT1↓, 1,   MMP13↓, 2,   MMP2↓, 10,   MMP3↓, 2,   MMP7↓, 2,   MMP9↓, 12,   MMPs↓, 5,   MUC1↓, 1,   N-cadherin↓, 7,   PKA↓, 1,   Rho↓, 1,   ROCK1↓, 1,   Slug↓, 8,   Smad1↓, 1,   SMAD2↓, 1,   SMAD3↓, 2,   Snail↓, 7,   SOX4↑, 1,   talin↓, 1,   TET1↑, 2,   TGF-β↓, 1,   TGF-β1↓, 1,   TIMP1↑, 2,   TIMP2↑, 1,   TIMP3↑, 1,   TSP-1↑, 1,   TumCI↓, 50,   TumCMig↓, 31,   TumCP↓, 20,   TumMeta↓, 14,   Twist↓, 5,   TXNIP↑, 1,   uPA↓, 2,   uPAR↓, 1,   Vim?, 1,   Vim↓, 5,   Zeb1↓, 3,   Zeb1↑, 1,   ZEB2↓, 1,   ZO-1↓, 1,   α-SMA↓, 3,   α-SMA↑, 1,   β-catenin/ZEB1↓, 6,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 9,   ATF4↑, 1,   ATF4↝, 1,   EGFR↓, 6,   HIF-1↓, 1,   Hif1a↓, 6,   NO↓, 1,   VEGF↓, 6,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 4,   GLUT3↓, 1,   P-gp/ABCB1↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↑, 1,   COX2/PTGS2↓, 1,   CRP↓, 1,   CXCR4↓, 3,   ICAM-1↓, 1,   IKKα↓, 1,   IL1β↓, 3,   IL6↓, 5,   IL8↓, 1,   Inflam↓, 2,   IRAK4↓, 1,   JAK1↓, 1,   JAK2↓, 2,   NF-kB↓, 9,   NF-kB↑, 1,   p‑NF-kB↓, 1,   PD-1↓, 1,   PGE2↓, 1,   Th1 response↑, 1,   TLR4↓, 1,   TNF-α↓, 2,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 2,   NLRP3↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   CDK6↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioEnh?, 1,   BioEnh↑, 1,   ChemoSen↑, 9,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   Dose↓, 1,   Dose↝, 2,   eff↓, 2,   eff↑, 8,   Half-Life↝, 1,   MDR1↓, 1,   MRP1/ABCC1↓, 1,   P450↓, 1,   RadioS↑, 3,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   BMPs↑, 1,   BP↓, 1,   CRP↓, 1,   EGFR↓, 6,   FOXM1↓, 1,   HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   IL6↓, 5,   Ki-67↓, 4,   LDH↓, 1,   LDH↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 2,   AntiTum↑, 2,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 1,   neuroP↑, 1,   OS↑, 1,   Risk↓, 2,   toxicity↓, 1,   TumVol↓, 2,   TumW↓, 2,   Weight∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 1,   Sepsis↓, 1,  
Total Targets: 305

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 4,   Catalase↑, 1,   GPx↑, 1,   GPx1↑, 1,   GSH↑, 1,   HO-1↑, 2,   Keap1↓, 1,   lipid-P↓, 3,   NRF2↑, 3,   ROS↓, 5,   ROS↑, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   Inflam↓, 4,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 3,   BioAv↝, 1,   Dose↝, 3,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   cardioP↑, 4,   chemoPv↑, 1,   hepatoP↑, 3,   neuroP↑, 6,   toxicity↓, 2,   toxicity↝, 1,  
Total Targets: 34

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion
21 Curcumin
15 Resveratrol
13 Quercetin
12 Honokiol
12 Shikonin
11 Berberine
11 Fisetin
10 Apigenin (mainly Parsley)
10 EGCG (Epigallocatechin Gallate)
10 Sulforaphane (mainly Broccoli)
9 Thymoquinone
8 Eugenol
8 Garcinol
7 Ashwagandha(Withaferin A)
7 Betulinic acid
7 Chlorogenic acid
7 Chrysin
7 Magnetic Fields
6 Metformin
6 Cinnamon
6 Dandelion Root
6 Emodin
6 Formononetin
6 Ginkgetin
6 Magnolol
6 Piperlongumine
5 Astragalus
5 Gemcitabine (Gemzar)
5 Ferulic acid
5 Hyperoside
5 Lycopene
5 Pterostilbene
4 Artemisinin
4 Baicalein
4 Carvacrol
4 Celastrol
4 Cyclopamine
4 Gambogic Acid
4 Isoliquiritigenin
4 Nimbolide
4 Phenethyl isothiocyanate
4 Rosmarinic acid
4 Silymarin (Milk Thistle) silibinin
4 Urolithin
3 Silver-NanoParticles
3 Alpha-Lipoic-Acid
3 Berbamine
3 Brucea javanica
3 brusatol
3 Capsaicin
3 Centella asiatica / Gotu kola → asiaticoside
3 chaetocin
3 Zinc
3 Propolis -bee glue
3 Crocetin
3 Copper and Cu NanoParticles
3 Evodiamine
3 Radiotherapy/Radiation
3 Gallic acid
3 Genistein (soy isoflavone)
3 Hydrogen Gas
3 Indole-3-carbinol
3 iodine
3 Juglone
3 Magnetic Field Rotating
3 Bicarbonate(Sodium)
3 Piperine
3 Whole Body Vibration
2 alpha Linolenic acid
2 Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry
2 Aspirin
2 Astaxanthin
2 Beta-Caryophyllene
2 Boron
2 Boswellia (frankincense)
2 α-Bisabolol / Chamomile oil
2 Caffeic Acid Phenethyl Ester (CAPE)
2 Celecoxib
2 Hydroxycinnamic-acid
2 Cynara scolymus/Globe Artichoke/Artichoke Extract
2 Dasatinib/Phyrago
2 Deguelin
2 Disulfiram
2 Ellagic acid
2 Paclitaxel/Taxol
2 Ginkgolic acids
2 Ginkgolide B
2 5-fluorouracil
2 Graviola
2 Grapeseed extract
2 Hibiscus sabdariffa
2 HydroxyTyrosol
2 isoflavones
2 isoorientin
2 isoquercitrin
2 Cisplatin
2 salinomycin
2 Sulfasalazine
2 Selenite (Sodium)
2 Aflavin-3,3′-digallate
2 Vitamin C (Ascorbic Acid)
1 1,8-Cineole
1 3-bromopyruvate
1 Ajoene (compound of Garlic)
1 DTS(dibenzyl trisulphide) from Anamu
1 Andrographis
1 Ascorbyl Palmitate
1 Melatonin
1 Aloe anthraquinones
1 Biochanin A
1 Atorvastatin
1 bempedoic acid
1 Bufalin/Huachansu
1 Bacopa monnieri
1 Butyrate
1 Carnosic acid
1 chitosan
1 Selenium NanoParticles
1 Chlorophyllin
1 Carvone
1 CUSP9
1 Cynaropicrin
1 Cysteamine
1 Dichloroacetate
1 Date Fruit Extract
1 Mistletoe/Viscum album Extracts
1 Ginkgo biloba-EGb 761
1 eicosapentaenoic acid
1 Sorafenib (brand name Nexavar)
1 Fucoidan
1 Galloflavin
1 Ginkgo biloba
1 Geraniol
1 Ginseng
1 γ-linolenic acid (Borage Oil)
1 Gossypol/AT-101
1 Proanthocyanidins
1 Hops (Humulus lupulus)
1 Isobavachalcone
1 IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate)
1 Isovitexin
1 Luteolin
1 Methyl salicylate / Sweet Birch oil
1 doxorubicin
1 immunotherapy
1 Noscapine
1 Oroxylin A
1 Oleuropein
1 Orlistat
1 Psoralidin
1 Docetaxel
1 Germacranolide sesquiterpene lactone
1 Rauwolfia serpentina/Indian Snakeroot
1 Salvia miltiorrhiza
1 Terpinen-4-ol / Tea Tree Oil
1 Thymol-Thymus vulgaris
1 Ursolic acid
1 Arsenic trioxide
1 Vitamin K2
1 VitK3,menadione
1 Vitexin
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:324  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page